08/01/2008
Koichi Sano, MD, PhD; Stephane G. Carlier, MD, PhD; Emilia Solinas, MD; Gregg W. Stone, MD, FACC, FSCAI; Jie Qian, MD; Gary S. Mintz, MD; Eduardo Missel, MD; Martin B. Leon, MD; Roxana Mehran, MD; Shoujie Shan, MD; Alexandra J. Lansky, MD; Jeffrey W. Moses, MD; Theresa Franklin-Bond, MS, PA; George D. Dangas, MD, PhD; Giora Weisz, MD; Paul Boland, BS; Michael B. Collins, MD; Nobuhiko Fujita, MD; Edward M. Kreps, MD; Issam Moussa, MD; Jose de Ribamar Costa, Jr., MD, PhD
Sirolimus-eluting and paclitaxel-eluting stents decrease neointimal hyperplasia leading to a reduction, but not elimination, of in-stent restenosis.1–4 Because sirolimus and paclitaxel decrease neointimal hyperplasia, restenosis is dependent...
Sirolimus-eluting and paclitaxel-eluting stents decrease neointimal hyperplasia leading to a reduction, but not elimination, of in-stent restenosis.1–4 Because sirolimus and paclitaxel decrease neointimal hyperplasia, restenosis is dependent...
Sirolimus-eluting and...